Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Pentamidine (VLX103) in HCC Undergoing Thermal Ablation
NCT02210182Phase 1Completed
- Sponsor
- Oncozyme Pharma
- Start
- Aug 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Oral Pentamidine with Placebo (2 arms). Primary endpoint: Pharmacokinetics (Hepatic Uptake) at 3 days. Started Aug 2014; status: completed.
02
Drugs
pentamidine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02210182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210182.